Cargando…
P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431088/ http://dx.doi.org/10.1097/01.HS9.0000971588.68510.b0 |
| _version_ | 1785091116820856832 |
|---|---|
| author | Yang, Fan Liu, Rui Fu, Zhonghua Xu, Teng Zheng, Peihao Feng, Shaomei Guo, Yuelu MA, Lixia Shi, Hui Deng, Biping Ke, Xiaoyan Hu, Kai |
| author_facet | Yang, Fan Liu, Rui Fu, Zhonghua Xu, Teng Zheng, Peihao Feng, Shaomei Guo, Yuelu MA, Lixia Shi, Hui Deng, Biping Ke, Xiaoyan Hu, Kai |
| author_sort | Yang, Fan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431088 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310882023-08-17 P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA Yang, Fan Liu, Rui Fu, Zhonghua Xu, Teng Zheng, Peihao Feng, Shaomei Guo, Yuelu MA, Lixia Shi, Hui Deng, Biping Ke, Xiaoyan Hu, Kai Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431088/ http://dx.doi.org/10.1097/01.HS9.0000971588.68510.b0 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yang, Fan Liu, Rui Fu, Zhonghua Xu, Teng Zheng, Peihao Feng, Shaomei Guo, Yuelu MA, Lixia Shi, Hui Deng, Biping Ke, Xiaoyan Hu, Kai P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title | P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title_full | P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title_fullStr | P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title_full_unstemmed | P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title_short | P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA |
| title_sort | p1173: early administration of polatuzumab vedotin as bridging cd19-specific chimeric antigen receptor t cell therapy is an effective strategy to improve survival in patients with r/r b-cell lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431088/ http://dx.doi.org/10.1097/01.HS9.0000971588.68510.b0 |
| work_keys_str_mv | AT yangfan p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT liurui p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT fuzhonghua p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT xuteng p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT zhengpeihao p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT fengshaomei p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT guoyuelu p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT malixia p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT shihui p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT dengbiping p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT kexiaoyan p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma AT hukai p1173earlyadministrationofpolatuzumabvedotinasbridgingcd19specificchimericantigenreceptortcelltherapyisaneffectivestrategytoimprovesurvivalinpatientswithrrbcelllymphoma |